Neoadjuvant adebrelimab combined with chemotherapy (cisplatin/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS)
Introduction Small-cell lung cancer (SCLC) is a highly malignant neuroendocrine tumour, and concurrent chemoradiotherapy is the current recommended treatment for limited-stage SCLC. However, the overall survival (OS) of patients with SCLC remains poor. Therefore, improving the survival of patients w...
Saved in:
Main Authors: | Yan Zhang, Qian Huang, Mengxia Li, Xi Zheng, Yanyang Liu, Long Tian, Guizhi Chen, Hongyu Xu, Daxing Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/15/1/e087302.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib, Ifosfamide, Carboplatin, and Etoposide in a Patient with HIV-Negative Relapsed Plasmablastic Lymphoma
by: Mehmet Akce, et al.
Published: (2016-01-01) -
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
by: Eisaku Miyauchi, MD, PhD, et al.
Published: (2025-03-01) -
Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study
by: Masaru Matsumoto, et al.
Published: (2025-01-01) -
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer
by: Zhiwei Chen, et al.
Published: (2025-01-01) -
Neoadjuvant programmed death ligand-1 with chemotherapy versus chemotherapy alone for limited-stage small-cell lung cancer: a retrospective study
by: Zhi Yang, et al.
Published: (2025-01-01)